REthinking Clinical Trials



Observing Oncotype DX ordering behaviour at 6 Ontario sites

Principal Investigator(s): Dr. Arif Awan NCT04131933
Only some patients with early-stage hormone receptor positive breast cancer benefit from chemotherapy which can have some significant side effects. Patients and clinicians rely on the classic factors such as patient’s tumor size, grade, age in a publicly available tool called PREDICT 2.1 as well as newer and expensive genomic tests looking at patient’s cancer genetic make-up to decide whether there’s a substantial benefit of chemotherapy. In this trial we are assessing how clinicians use PREDICT 2.1 and the genomic tests in their practice with patients to guide decision-making around adjuvant chemotherapy.

Funded by a OICR Health Services Research grant.

Sites: Cancer Centre of Southeastern Ontario (Kingston) Grand River Hospital (Kitchener Waterloo) Markham Stouffville Hospital The Ottawa Hospital Thunder Bay Regional Health Sciences Centre Windsor Regional Hospital

Tags: Early stage Breast Cancer


  • Does preemptive availability of PREDICT 2.1 results change ordering practices for Oncotype DX? A multi-center prospective cohort study. Awan et al, 2023. Under review

Previous Trial and Economic Analysis:

  • Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. Robertson et all, 2019. PMID: 30672056
  • Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer. De Lima et al, 2019. PMID: 31287198
  • Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information. Robertson et al, 2019. PMID: 31551182